Malignant News and Research

RSS

COVID-19's unseen impact: study reveals surge in home deaths across 32 countries

Trends in places of death across 32 countries during and before the COVID-19.

5 Jan 2024

High-resolution map of the neuroblastoma immune landscape points to new target for immunotherapy

A detailed 'atlas' of neuroblastoma tumors points to a new target for immunotherapy. Scientists from the Princess Máxima Center for Pediatric Oncology in the Netherlands mapped this childhood tumor at the level of individual cancer and immune cells.

4 Jan 2024

HPV infection linked to doubled risk of thyroid cancer

A study in Taiwan involving 3,062 thyroid cancer patients and 9,186 controls finds that HPV infection more than doubles the risk of developing thyroid cancer, providing the first evidence of a carcinogen for this common endocrine cancer.

4 Jan 2024

Researchers establish the first international criteria for standardized imaging of gliomas

Diffuse gliomas are malignant brain tumors and cannot be optimally examined by conventional imaging using MRI. Amino acid PET can better visualize the activity and spread of gliomas.

3 Jan 2024

New standardized criteria for diagnosing brain tumors with amino acid PET

Diffuse gliomas are malignant brain tumors that cannot be optimally examined by means of conventional MRI imaging. So-called amino acid PET scans are better able to image the activity and spread of gliomas.

3 Jan 2024

GFH009 disrupts growth signals and triggers apoptosis in hematologic malignancies

A new research paper was published in Oncotarget's Volume 14 on December 20, 2023, entitled, "The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies."

28 Dec 2023

New drug screening system helps uncover promising target for pancreatic cancer treatments

A drug screening system that models cancers using lab-grown tissues called organoids has helped uncover a promising target for future pancreatic cancer treatments, according to a new study from researchers at Weill Cornell Medicine.

26 Dec 2023

Study highlights underutilization of end-of-life care for patients with malignant urinary obstruction

Less than half of patients with malignant ureteral obstruction (MUO) – a serious complication of advanced cancer, with a poor prognosis – receive palliative care (PC) for their condition, reports a paper in the January issue of Urology Practice, an Official Journal of the American Urological Association (AUA).

21 Dec 2023

Rapid identification of disease-causing bacteria using Raman spectroscopy

Study in BioRisk explores the use of Raman spectroscopy for rapid identification of Pseudomonas aeruginosa, a bacteria causing serious human diseases, demonstrating its potential as a quick and efficient diagnostic tool.

14 Dec 2023

Developing a virtual twin for personalized cancer treatment with CAR-T cell therapy

In recent years, cancer immunotherapies have established themselves as a further pillar of medical oncology alongside traditional treatment options (surgery, radiotherapy and chemotherapy).

13 Dec 2023

Organoid study opens new avenues in pulmonary neuroendocrine cancer therapy

Researchers performed a molecular analysis of neuroendocrine neoplasm (NEN) patient-derived tumor organoids (PDTOs) and their parental neoplasms.

13 Dec 2023

Lymphatic fluid from surgical drains could inform more precise treatments for head and neck cancer

Lymphatic fluid from surgical drains, which is usually tossed in the trash, is a treasure in the hands of University of Pittsburgh and Washington University School of Medicine in St. Louis researchers who found that this liquid could inform more precise treatments for patients with head and neck cancer caused by human papillomavirus (HPV).

11 Dec 2023

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center.

11 Dec 2023

The association between viral infections and glioma risk

The causal relationship between viral infection and glioma.

7 Dec 2023

Study uses game theory to show low tumor heterogeneity leads to higher aggression

A study by the University of the Basque Country (UPV/EHU) uses game theory to establish that tumors with less cellular heterogeneity are more aggressive.

5 Dec 2023

New drug combination may improve treatment for rare nerve sheath tumors

Combining a pair of experimental drugs may help treat malignant peripheral nerve sheath tumors with fewer harmful side effects, according to preliminary animal studies led by investigators at the Johns Hopkins Kimmel Cancer Center and Johns Hopkins Drug Discovery.

1 Dec 2023

Drug-eluting hydrogel has enhanced capabilities for treating hepatocellular carcinoma

Scientists from the Terasaki Institute for Biomedical Innovation (TIBI) have developed an injectable or catheter-administered hydrogel with enhanced capabilities for treating hepatocellular carcinoma (HCC), a deadly form of liver cancer.

29 Nov 2023

New cortex organoids more accurately represent the human brain

Essential features of the cortex, an important part of the human brain and its development, are more accurately captured in organoids generated by researchers of the Princess Máxima Center for pediatric oncology and the Hubrecht Institute.

28 Nov 2023

RNA-based therapy shows promise for treating leukemia in animal models

Each year, about 13,000 people in Deutschland are diagnosed with leukemia, an umbrella term that encompasses various forms of blood cancer.

27 Nov 2023

JMU Würzburg professor wins ERC Consolidator Grant to advance research on ferroptosis

With the coveted Consolidator Grants totalling two million euros, the European Research Council (ERC) supports outstanding scientists whose work promises further top achievements. José Pedro Friedmann Angeli, Professor of Translational Cell Biology at Rudolf Virchow Centre - Centre for Integrative and Translational Bioimaging at Julius-Maximilians-Universität (JMU) Würzburg, now belongs to this group.

23 Nov 2023